The trademark application QZALLUS was filed by Genzyme Corporation, a U.S. corporation (the "Applicant"). The application was published for oppositions on July 15, 2020, and it was registered by office on October 23, 2020 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on February 1, 2022. Change of name and address of the trademark registration was recorded on August 16, 2022.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system
Pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases
Pharmaceutical preparations for the treatment of rare blood disorders, pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections.